Targets › NA
3 programs from 3 companies in 3 trials: 2 Phase 3, 1 Phase 2; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on NA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Capital Medical University | Suraxavir marboxil Neuraminidase inhibitor | NA | Phase 3 | Influenza | Mar 2027 |
| University Medical Centre Ljubljana | oseltamivir Neuraminidase inhibitor | NA | Phase 3 | Influenza | Mar 2028 |
| George Washington University | Zanamivir Neuraminidase inhibitor | NA | Phase 2 | Dengue Fever | Aug 2027 |
Influenza (2) Dengue Fever (1)
small molecule (3)
Capital Medical University (1) George Washington University (1) University Medical Centre Ljubljana (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.